Compare PESI & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PESI | GBIO |
|---|---|---|
| Founded | 1990 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Environmental Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 243.9M | 36.3M |
| IPO Year | 1992 | 2020 |
| Metric | PESI | GBIO |
|---|---|---|
| Price | $14.62 | $5.62 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $8.88 |
| AVG Volume (30 Days) | ★ 98.1K | 62.7K |
| Earning Date | 11-10-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $60,661,000.00 | $15,270,000.00 |
| Revenue This Year | $9.91 | N/A |
| Revenue Next Year | $62.48 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.25 | $3.00 |
| 52 Week High | $16.50 | $10.40 |
| Indicator | PESI | GBIO |
|---|---|---|
| Relative Strength Index (RSI) | 63.43 | 56.24 |
| Support Level | $14.24 | $5.31 |
| Resistance Level | $14.88 | $5.70 |
| Average True Range (ATR) | 0.61 | 0.16 |
| MACD | 0.15 | 0.01 |
| Stochastic Oscillator | 89.17 | 67.39 |
Perma-Fix Environmental Services Inc is a provider of both nuclear services and the management of nuclear and mixed waste. The company operates through two segments: The treatment segment offers nuclear, low-level radioactive, Mixed, hazardous and non-hazardous waste treatment, processing and disposal services, and the Services segment which generates the majority of the revenue, provides on-site waste management services to commercial and government customers, technology-based services, construction, logistics, and transportation services among others.
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.